Related Experiment Video
Updated: May 24, 2026
Fetal Echocardiography and Pulsed-wave Doppler Ultrasound in a Rabbit Model of Intrauterine Growth Restriction
Published on: June 29, 2013
The value of early second trimester PAPP-A and ADAM12 in screening for pre-eclampsia
Jonathan P Bestwick1, Lynne M George, Tiesheng Wu
1Wolfson Institute of Preventive Medicine, Barts and London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ. j.p.bestwick@qmul.ac.uk
Objective:
To estimate the pre-eclampsia screening performance of PAPP-A (pregnancy-associated plasma protein-A) and ADAM12 (A Disintegrin And Metalloprotease 12) in the early second trimester of pregnancy.
Methods:
Stored frozen serum samples from a previously published nested case-control study comprising 77 women who developed pre-eclampsia and 224 unaffected controls were thawed and assayed for PAPP-A and ADAM12. Levels were converted into multiple of the unaffected median (MoM) values.
Results:
Neither PAPP-A or ADAM12 were significantly different in women who developed pre-eclamspia compared with unaffected controls (PAPP-A: 0.97 MoM [95% confidence interval 0.73 to 1.25], ADAM12: 1.01 MoM [0.91 to 1.13]).
Conclusion:
Our results do not support the use of PAPP-A or ADAM12 in early second trimester antenatal screening for pre-eclampsia.
